BiomX Inc. (PHGE): History, Ownership, Mission, How It Works & Makes Money

Ever heard of BiomX Inc. (PHGE) and wondered what they're all about? This clinical-stage microbiome company is making waves with its innovative approach to fighting chronic diseases using phage therapies, but how exactly do they operate and generate revenue? Keep reading to discover the history, ownership structure, mission, and the intricate workings of this pioneering biotech firm, including a look at their financial performance in 2024.

BiomX Inc. (PHGE) History

BiomX Inc. Founding Timeline

Year established

BiomX was co-founded in 2015.

Original location

The company is based in Ness Ziona, Israel, with a U.S. office in Cambridge, MA.

Founding team members

The founding team included:

• Eran Ofir
• Raya Sorkin
• Tim Lu

Initial capital/funding

In 2015, BiomX raised an initial $24 million in a Series A funding round led by OrbiMed and Johnson & Johnson Innovation JJDC, Inc.

BiomX Inc. Evolution Milestones

BiomX Inc. Transformative Moments

• Merger with Chardan Healthcare Acquisition Corp (2019): This merger was a pivotal moment, providing BiomX with the necessary capital to advance its clinical programs and expand its research efforts. The transition to a publicly traded company significantly increased its visibility and access to capital markets.
• Strategic Collaborations: Collaborations, such as the one with Boehringer Ingelheim, have been crucial for BiomX. These partnerships provide not only financial support but also access to expertise and resources that accelerate the development and commercialization of its therapies.
• Clinical Trial Milestones: The progression of BX001 through clinical trials represents a major achievement. Positive results from these trials validate the company's technology and pave the way for potential regulatory approvals and commercial success.

To gain more insights into the company's financial standing, consider reading: Breaking Down BiomX Inc. (PHGE) Financial Health: Key Insights for Investors

BiomX Inc. (PHGE) Ownership Structure

BiomX Inc. operates with a mixed ownership structure, encompassing public shareholders and significant institutional investors, influencing its strategic decisions and corporate governance.

BiomX Inc.'s Current Status

BiomX Inc. is a publicly traded company, listed on the NYSE American under the ticker symbol PHGE. This allows the company to raise capital through the issuance of stock and makes it subject to regulatory oversight and reporting requirements by the Securities and Exchange Commission (SEC).

BiomX Inc.'s Ownership Breakdown

Understanding the ownership structure of BiomX Inc. provides insights into who has influence over the company's decisions. Here's a breakdown of the ownership as of the latest available data:

BiomX Inc.'s Leadership

The leadership team is crucial for guiding the company's strategy and operations. Here are some of the key leaders at BiomX Inc.:

• Eran Ofir, PhD: Chief Executive Officer
• Assaf Oron, PhD: Chief Business Officer
• Marina Wolf, PhD: Chief Scientific Officer
• No Offer Given: Chief Financial Officer

To gain more insight into the strategic direction of the company, explore: Mission Statement, Vision, & Core Values of BiomX Inc. (PHGE).

BiomX Inc. (PHGE) Mission and Values

BiomX Inc. is dedicated to pioneering innovative solutions in the microbiome field to improve patient health. The company focuses on developing therapies that target specific harmful bacteria in the human microbiome, addressing unmet needs in various diseases.

BiomX Inc.'s Core Purpose

Official mission statement

While a direct, concise mission statement is not explicitly available in the provided search results, BiomX's mission can be inferred from its activities and focus. BiomX is dedicated to discovering and developing innovative microbiome-based therapies to improve human health. This involves:

• Developing therapies that target specific disease-causing bacteria.
• Advancing microbiome research to create effective treatments for unmet medical needs.
• Utilizing a unique platform to identify and validate potential drug candidates.

Vision statement

Similarly, a specific vision statement is not provided in the search results. However, BiomX's vision can be understood as aiming to be a leader in microbiome-based therapeutics, striving to:

• Transform the treatment landscape for diseases linked to the microbiome.
• Establish a broad pipeline of innovative microbiome-based products.
• Improve patient outcomes through targeted and effective therapies.

Company slogan/tagline

No specific company slogan or tagline was found in the provided search results. Without an official tagline, it's challenging to definitively state one. For more insights into BiomX Inc., check out: Exploring BiomX Inc. (PHGE) Investor Profile: Who’s Buying and Why?

BiomX Inc. (PHGE) How It Works

BiomX Inc. is a clinical-stage biotechnology company focused on developing therapies that target specific harmful bacteria in chronic diseases, primarily using bacteriophages, which are viruses that infect and kill bacteria, to address conditions like inflammatory bowel disease (IBD), colorectal cancer, and atopic dermatitis.

BiomX Inc.'s Product/Service Portfolio

BiomX Inc.'s Operational Framework

BiomX operates through a structured process of identifying, isolating, and engineering bacteriophages to target specific bacteria associated with various diseases. This involves:

• Target Identification: Identifying specific bacteria that play a role in causing or exacerbating chronic diseases.
• Phage Discovery: Screening environmental samples to discover bacteriophages that can selectively kill the target bacteria.
• Phage Engineering: Genetically modifying the bacteriophages to enhance their efficacy, specificity, and stability.
• Pre-clinical Development: Conducting in vitro and in vivo studies to evaluate the safety and efficacy of the engineered bacteriophages.
• Clinical Trials: Progressing potential therapies through Phase 1, Phase 2, and Phase 3 clinical trials to demonstrate safety and efficacy in humans.
• Manufacturing: Scaling up the production of the bacteriophage therapies to meet clinical and commercial demand.
• Partnerships: Collaborating with pharmaceutical companies and academic institutions to accelerate the development and commercialization of their products.

The company's financial health is crucial to its operational success, considering the high costs associated with drug development. As of the fiscal year 2024, BiomX reported a net loss of $43.4 million, with research and development expenses accounting for a significant portion at $27.5 million. The company is focused on managing its resources effectively to advance its clinical programs.

BiomX Inc.'s Strategic Advantages

• Proprietary Technology Platform: BiomX has a robust platform for discovering, engineering, and developing bacteriophage therapies, giving them a competitive edge in the microbiome therapeutics field.
• Targeted Approach: Their therapies are designed to selectively kill harmful bacteria while sparing beneficial bacteria, potentially leading to fewer side effects compared to broad-spectrum antibiotics.
• Diverse Pipeline: BiomX is developing therapies for a range of chronic diseases, reducing the risk associated with relying on a single product.
• Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies provide access to additional expertise, funding, and resources.

To gain a deeper understanding of the investors behind BiomX, explore this insightful resource: Exploring BiomX Inc. (PHGE) Investor Profile: Who’s Buying and Why?

BiomX Inc. (PHGE) How It Makes Money

BiomX Inc. is a clinical-stage biotechnology company that focuses on developing microbiome-based therapies, primarily relying on research and development collaborations, licensing agreements, and, potentially in the future, direct sales of its pharmaceutical products to generate revenue.

BiomX Inc.'s Revenue Breakdown

As a clinical-stage company, BiomX's revenue streams are still evolving. Here’s a potential breakdown based on the company's activities:

BiomX Inc.'s Business Economics

BiomX operates under a business model common to biotechnology firms, characterized by high upfront research and development costs and the potential for substantial returns upon successful commercialization of its products.

• R&D Investment: Significant capital is allocated to discovering and developing novel bacteriophage-based therapies.
• Partnerships: Strategic alliances with larger pharmaceutical companies can provide funding and expertise, sharing the financial burden and risk.
• Intellectual Property: Patents and proprietary technologies are crucial assets, protecting their innovations and providing a competitive advantage.
• Clinical Trials: The cost and success of clinical trials heavily influence the company's valuation and ability to attract investment.

BiomX Inc.'s Financial Performance

Given its status as a clinical-stage biotech company, BiomX's financial performance is heavily scrutinized for its cash runway, burn rate, and the progress of its clinical programs.

• Cash Reserves: Monitoring cash and cash equivalents is vital to ensure the company can fund ongoing operations and clinical trials. As of December 31, 2023, BiomX Inc. reported total cash, cash equivalents and short-term deposits of $38.9 million.
• Operating Expenses: A significant portion of expenses is related to research and development. For the year ended December 31, 2023, research and development expenses were $27.9 million, compared to $33.7 million for the year ended December 31, 2022.
• Net Loss: As is typical for biotech companies in the development phase, BiomX experiences net losses as it invests heavily in R&D without significant product revenue. BiomX Inc. reported a net loss of $33.9 million for the year ended December 31, 2023, compared to a net loss of $41.3 million for the year ended December 31, 2022.
• Revenue: Revenues are primarily derived from collaborative agreements. For the year ended December 31, 2023, BiomX Inc. reported revenue of $0.8 million, compared to $2.4 million for the year ended December 31, 2022.

To gain more insights into BiomX Inc.'s financial health, check this out: Breaking Down BiomX Inc. (PHGE) Financial Health: Key Insights for Investors

BiomX Inc. (PHGE) Market Position & Future Outlook

BiomX Inc. is a clinical-stage biotechnology company focused on developing novel bacteriophage therapies targeting specific pathogenic bacteria. While the company navigates a competitive and evolving market, its innovative approach to addressing unmet needs in chronic diseases holds promise for future growth.

Competitive Landscape

Opportunities & Challenges

Industry Position

BiomX Inc. operates within the competitive biotechnology industry, specifically focusing on bacteriophage technology. Key aspects of its industry positioning include:

• Innovative Approach: Stands out with its focus on phage therapy, offering a unique approach to combatting bacterial infections and related diseases.
• Clinical Stage: As a clinical-stage company, it is actively involved in advancing its product candidates through clinical trials, a critical phase for demonstrating efficacy and safety.
• Targeted Therapies: Aims to develop therapies that precisely target harmful bacteria while preserving the beneficial microbiome.

Read more about the company's mission, vision, and core values: Mission Statement, Vision, & Core Values of BiomX Inc. (PHGE).